Skip to main content
Premium Trial:

Request an Annual Quote

International VC Firm Still Has Half of $300M Fund Available

NEW YORK, Aug. 27 - German life-science VC firm Techno Venture Management has spent about half of the $296 million fund raised last November, a company official told GenomeWeb.


The cash was spent among 13 startup biotechs, said TVM spokeswoman Theresia Wermelskirchen. She added that the company, a specialist in early-stage companies, "still has room for more investments."


Munich-based TVM had said last November it planned to focus its investments in early-stage companies developing platform technologies to improve the drug-discovery process, as well as in companies developing therapeutics. Later-stage deals will be considered.

The company said it would be primarily interested in companies based in Germany, Switzerland, Austria, the UK, and the US. It has previously invested in companies such as GPC Biotech, MediGene, DeveloGen, and Evotec BioSystems.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.